Lilly(Eli) & Company risk profile
33 Normal where most of the sector sits
Measured 21 October 2026 from LLY's filed statements. Recomputed nightly.
33 (Normal), driven by Concentration at 64, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 24 | Normal | Stable | One-year price volatility — 34.4% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 48 | Elevated | Easing | Capital spending against operating cash — 0.65x |
| Leverage and coverage | 16 | Contained | Easing | Current ratio — 1.58x |
| Competitive position | 17 | Contained | Stable | R&D-intensity gap against peers — +0.7 percentage points |
| Concentration | 64 | Stretched | Stable | Geographic concentration — 4,784 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51Abbott Laboratories 40
Financials, valuation and price history for Lilly(Eli) & Company